There is significant interest in the use of GLP‐1R agonists as therapeutic agents in neurodegenerative diseases, particularly in Alzheimer's and Parkinson's diseases, and in mood disorders 4, 114. The gene discussed is GLP1R; the disease is Parkinson disease.